Navigation Links
Data From QNEXA Sequel Study Featured at the 47th EASD Annual Meeting
Date:9/16/2011

n the FDA's CRL; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy or FORTRESS; the FDA's interpretation of and agreement with the information VIVUS submitted and may submit relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study, or OB-305; the FDA's requests, if any, to conduct additional prospective studies or retrospective observational studies or to provide further analysis of clinical trial data; the review and questions from the EMA and CHMP on the MAA; substantial competition; the impact on future sales based on specific indication and contraindications contained in the label and the extent of the Risk Evaluation and Mitigation Strategies program; uncertainties of litigation and intellectual property and patent protection; reliance on sole-source suppliers; limited sales and marketing resources and dependence upon third parties; risks related to the development of innovative products; risks related to the failure to obtain FDA or foreign authority clearances or approval; noncompliance with FDA or foreign regulations; and our dependence on the performance of our collaborative partners. As with any pharmaceutical in development, there are significant risks in the development, the regulatory approval, and commercialization of new products. There are no guarantees that our response to the FDA's CRL or the results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy and subsequent meetings and communications will be sufficient to satisfy the FDA's safety concerns, that the FDA will not require us to conduct any additional  prospective studies or retrospective observational studies, or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to up
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. VIVUS Provides Regulatory Update on QNEXA
2. Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
3. Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity
4. Multiple Presentations Featuring QNEXA® Data to be Presented at the European Congress on Obesity
5. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
6. Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits
7. Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting
8. VIVUS Provides Regulatory Update on QNEXA NDA
9. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
10. A Majority of Surveyed PCPs and Endocrinologists Indicate that they will Prescribe Contrave, Lorqess and Qnexa if these Therapies are Approved for Obesity
11. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 CVS Caremark Corporation (NYSE: ... approved a quarterly dividend of $0.275 (27.5 cents) per share ... August 1, 2014, to holders of record on July 21, ... Caremark is dedicated to helping people on their path to ... the United States . Through the company,s more ...
(Date:1/15/2014)... Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition of ... Size, Share, Growth, Trends And Forecast, 2013 - 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 ) Dental consumables ... to treat dental impairments, for tooth restoration and in ...
(Date:1/15/2014)... 15, 2014 Massachusetts General Hospital (MGH), the ... ) announced today that they have launched a ... therapeutic targets and develop novel therapies for inflammatory ... millions worldwide. The MGH-Broad-Amgen collaboration brings together scientists ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
(Date:7/11/2014)... When the mercury rises, heat can strain the limits ... takes on a heavier load in hot weather to keep ... the Harvard Men's Health Watch . , For otherwise ... knowing their limits and drinking enough fluids. But what about ... sensitive to the heat," says Dr. Joanne Foody, Director of ...
(Date:7/11/2014)... 11, 2014 Los Angeles dental ... he uses mini and full mouth implants to replace ... feature that distinguishes dental implants from other tooth replacements: ... the crowns. This alone prevents the long-term complications of ... advantages related to comfort, appearance and systemic health. Mini ...
(Date:7/11/2014)... A new study challenges the widely held belief that light ... Researchers analyzed more than 50 studies that examined drinking habits ... found that those with a form of a gene tied ... gene affects how a person,s body breaks down alcohol, resulting ... this variant has been shown to lead to lower drinking ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Cancer researchers ... have a significant impact on how patients respond to ... for mesothelioma. Surviving Mesothelioma has the full story. ... , Researchers at the University of Ljubljana and the ... pemetrexed for different types of polymorphisms. They found ...
(Date:7/11/2014)... 11, 2014 Anterior Cruciate Ligament (ACL) ... the type of material used to create a new ... game, say researchers presenting their work today at the ... Medicine ( AOSSM ). , “Our study ... (tissue harvested from a donor) fail more frequently than ...
Breaking Medicine News(10 mins):Health News:Take Common Sense Steps to Stay Safe This Summer, from the July 2014 Harvard Men's Health Watch 2Health News:Take Common Sense Steps to Stay Safe This Summer, from the July 2014 Harvard Men's Health Watch 3Health News:Dental Implant Dentist, Kevin Sands DDS, Now Uses Mini and Full Mouth Implants to Replace Missing Teeth 2Health News:A Little Alcohol May Not Be Good for Your Heart After All 2Health News:New Research Finds Genetic Variables Impact Chemotherapy Response, According to Surviving Mesothelioma 2Health News:ACL Reconstructions May Last Longer With Autografts 2
... disorders in this country has nearly doubled in the past ... psychologists and therapists are charged with the task, but many ... date and lack scientific rigor. This is in part because ... programs and for-profit training centersare not grounded in science. ...
... today for excellence in research, advancing oral health ... receive the 2009 American Dental Association,s (ADA) Gold Medal Award ... presentation during a meeting of the ADA,s House of ... every three years, the award honors individuals who contribute to ...
... Beginning October 1st, The Peninsula Chicago will dedicate itself to ... several cancer research and education organizations. , "We all know ... some way and this is why we at The Peninsula ... manager of The Peninsula Chicago. "In addition to the initiatives ...
... the largest non-government, not-for-profit funding source of cancer research ... research and training grants totaling $45,097,000 to 61 institutions ... 2009. The grants go into effect beginning January 1, ... Cancer Society has funded research and training of health ...
... ... Medical Center,s Emergency Department will begin using a new procedure, called therapeutic hypothermia, to ... , ... 2009 -- On October 19, 2009, Baptist Medical Center,s Emergency Department will ...
... Organization Exclusively for LTC Consumers Receives ... (formerly the National Citizens, Coalition for Nursing Home Reform) announced ... will help strengthen the organization,s role as a voice for ... organization exclusively for residents and their families and is a ...
Cached Medicine News:Health News:Where's the science? The sorry state of psychotherapy 2Health News:ADA's 2009 Gold Medal Award Presentation Set for 150th Annual Session 2Health News:The Peninsula Chicago Gives Back During Breast Cancer Awareness Month 2Health News:American Cancer Society awards 94 new research and training grants at 61 institutions nationwide 2Health News:American Cancer Society awards 94 new research and training grants at 61 institutions nationwide 3Health News:American Cancer Society awards 94 new research and training grants at 61 institutions nationwide 4Health News:American Cancer Society awards 94 new research and training grants at 61 institutions nationwide 5Health News:Baptist Using Therapeutic Hypothermia to Save Heart Attack Patients 2Health News:Long-Term Care Consumer Voices Strengthened 2
... Addressing the key clinical and economic issues ... System is designed to maximize tension control ... The system combines efficient instrumentation with a ... Grip system is indicated for general orthopaedic ...
... In 1985, the worlds first ... by Howmedica Osteonics as a means ... wire for trochanteric reattachment procedures. Today, ... papers demonstrating clinical successes, the Dall-Miles™ ...
The Assistant Free Self-Retaining Hip Surgery Retractor System is used for hip arthroplasty and hip fracture surgery....
... have become the accepted standard for,excellence and ... AML Total Hip System was the first ... meet the needs for biological fixation in ... 15 years of documented clinical performance, the ...
Medicine Products: